Loading
Argatroban · Regulatory label update
U.S. Food and Drug Administration · June 26, 2026
An action by a regulator. Authoritative on labelling and availability.
This is an FDA supplemental approval for a labeling change to argatroban in 0.9% sodium chloride (250 mg/250 mL solution). The record documents a regulatory action only and does not contain clinical trial data, efficacy results, or safety findings.
Regulatory label update.
This is an FDA supplemental approval for a labeling change to argatroban in 0.9% sodium chloride (250 mg/250 mL solution). The record documents a regulatory action only and does not contain clinical trial data, efficacy results, or safety findings.
This record does not contain clinical trial results, efficacy data, or safety findings
The source did not state who this applies to in practice.
FDA supplemental approval for labeling change to an existing argatroban product; regulatory action, not clinical evidence of efficacy or safety.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Drugs@FDA record for application NDA206769. This is a regulatory action record, not a clinical study. Brand name: ARGATROBAN IN 0.9% SODIUM CHLORIDE. Active ingredient: ARGATROBAN. Sponsor: TEVA PHARMS USA. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-06-26. Products: ARGATROBAN IN 0.9% SODIUM CHLORIDE, INJECTABLE, INTRAVENOUS, ARGATROBAN 250MG/250ML (1MG/ML).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.